Influence of baseline demographics/disease characteristics on efficacy of an oral selective TYK2 inhibitor, BMS-986165, in patients with moderate to severe plaque psoriasis: Phase 2, randomized, placebo-controlled trial. J of Skin [Internet]. 2019 Nov. 9 [cited 2025 Apr. 19];3:S14. Available from: https://skin.dermsquared.com/skin/article/view/741